Thornburg Investment Management Boosted At&T Com (T) Stake By $22.35 Million; Fate Therapeutics (FATE) Shorts Raised By 4.03%

November 14, 2017 - By Richard Conner

Fate Therapeutics Incorporated (NASDAQ:FATE) had an increase of 4.03% in short interest. FATE’s SI was 1.17M shares in November as released by FINRA. Its up 4.03% from 1.12M shares previously. With 250,100 avg volume, 5 days are for Fate Therapeutics Incorporated (NASDAQ:FATE)’s short sellers to cover FATE’s short positions. The SI to Fate Therapeutics Incorporated’s float is 4.89%. About 17,496 shares traded. Fate Therapeutics Inc (NASDAQ:FATE) has risen 166.12% since November 14, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Thornburg Investment Management Inc increased At&T Inc Com (T) stake by 10.97% reported in 2017Q2 SEC filing. Thornburg Investment Management Inc acquired 604,006 shares as At&T Inc Com (T)’s stock declined 7.81%. The Thornburg Investment Management Inc holds 6.11M shares with $230.49M value, up from 5.51 million last quarter. At&T Inc Com now has $207.50B valuation. The stock declined 1.08% or $0.37 reaching $33.8 on the news. About 4.55 million shares traded. AT&T Inc. (NYSE:T) has declined 0.52% since November 14, 2016 and is downtrending. It has underperformed by 17.22% the S&P500.

Investors sentiment decreased to 1.43 in Q2 2017. Its down 4.97, from 6.4 in 2017Q1. It turned negative, as 11 investors sold Fate Therapeutics Inc shares while 12 reduced holdings. 19 funds opened positions while 14 raised stakes. 25.76 million shares or 48.07% less from 49.60 million shares in 2017Q1 were reported. Bridgeway Capital Management holds 0.01% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 250,000 shares. Neuberger Berman Group Inc Ltd Liability Company reported 49,700 shares. Redmile Grp Limited Co holds 0.28% or 1.42M shares. Nationwide Fund Advisors stated it has 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Goldman Sachs Inc holds 0% in Fate Therapeutics Inc (NASDAQ:FATE) or 111,775 shares. Pennsylvania-based Vanguard has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Wells Fargo & Mn reported 0% in Fate Therapeutics Inc (NASDAQ:FATE). Jacobs Levy Equity Management invested in 50,004 shares. State Common Retirement Fund owns 40,500 shares or 0% of their US portfolio. Strs Ohio reported 0% in Fate Therapeutics Inc (NASDAQ:FATE). Connor Clark And Lunn Inv Management Ltd invested in 63,500 shares. Schwab Charles Mngmt Inc stated it has 66,000 shares. First Manhattan reported 0% stake. Tci Wealth has 800 shares for 0% of their portfolio. Panagora Asset reported 29,510 shares stake.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $171.75 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 9 analyst reports since October 6, 2015 according to SRatingsIntel. Wells Fargo initiated the shares of FATE in report on Friday, December 4 with “Outperform” rating. The firm has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The rating was initiated by TH Capital on Thursday, September 22 with “Buy”. H.C. Wainwright reinitiated it with “Buy” rating and $7 target in Thursday, October 12 report. As per Thursday, September 22, the company rating was initiated by Roth Capital. As per Wednesday, November 1, the company rating was maintained by BMO Capital Markets. Raymond James initiated the stock with “Outperform” rating in Tuesday, October 6 report. As per Tuesday, November 8, the company rating was maintained by Wedbush. Leerink Swann initiated Fate Therapeutics Inc (NASDAQ:FATE) on Friday, September 8 with “Buy” rating.

Thornburg Investment Management Inc decreased Netflix Inc (NASDAQ:NFLX) stake by 131,538 shares to 47,532 valued at $7.10 million in 2017Q2. It also reduced Unsp Adr stake by 192,981 shares and now owns 787,320 shares. Proofpoint Inc (NASDAQ:PFPT) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :